DAX23.092 -0,8%Est505.515 -1,0%MSCI World4.343 -0,1%Top 10 Crypto11,72 -3,4%Nas22.273 +0,9%Bitcoin73.252 -0,9%Euro1,1515 ±0,0%Öl62,56 -1,0%Gold4.066 -0,3%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 DroneShield A2DMAA Siemens Energy ENER6Y RENK RENK73 Amazon 906866 Alphabet A (ex Google) A14Y6F Deutsche Telekom 555750 Tesla A1CX3T Palantir A2QA4J Lufthansa 823212 Infineon 623100 BASF BASF11 SAP 716460 TKMS thyssenkrupp Marine Systems TKMS00
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX geht bei über 23.000 Punkten ins Wochenende -- Wall Street höher -- Portfolio von NVIDIA -- Bitcoin & Co. tiefrot -- D-Wave, Novo Nordisk, Siemens Energy, DroneShield, Rheinmetall, RENK im Fokus
Top News
Eli Lilly-Aktie fest: Novo Nordisk-Konkurrent erstmals über 1 Billion Dollar wert Eli Lilly-Aktie fest: Novo Nordisk-Konkurrent erstmals über 1 Billion Dollar wert
Die Highlights und Lowlights im TecDAX: Gewinner und Verlierer der KW 47 im Überblick Die Highlights und Lowlights im TecDAX: Gewinner und Verlierer der KW 47 im Überblick
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Oncolytics Biotech Aktie

Kaufen
Verkaufen
1,01 USD +0,02 USD +1,52 %
nachbörslich
BTT
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.86,42 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2JMW5

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINCA6823108759

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolONCY

Oncolytics Biotech Aktien News

DatumMeistgelesen
PR NewswireOncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care
PR NewswireOncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care
PR NewswireOncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada
PR NewswireOncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada
PR NewswireOncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study
PR NewswireOncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study
PR NewswireOncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion
PR NewswireOncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion
PR NewswireOncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions
PR NewswireOncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions
PR NewswireOncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors
PR NewswireOncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors
PR NewswireOncolytics Biotech® Announces Upcoming Investor Conferences in September
PR NewswireOncolytics Biotech® Announces Upcoming Investor Conferences in September
PR NewswireOncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
PR NewswireOncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
PR NewswireOncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep
PR NewswireOncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep
PR NewswireOncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange
PR NewswireOncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange
PR NewswireOncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results
PR NewswireOncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results
PR NewswireOncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End
PR NewswireOncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End
PR NewswireKey Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential
PR NewswireKey Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential
PR NewswireOncolytics Biotech® Regains Compliance with Nasdaq Trading Rules
PR NewswireOncolytics Biotech® Regains Compliance with Nasdaq Trading Rules
PR NewswireOncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types
PR NewswireOncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types
PR NewswireOncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers
PR NewswireOncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers
PR NewswireOncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies
PR NewswireOncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies
PR NewswireOncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy
PR NewswireOncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy
PR NewswireOncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs
PR NewswireOncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs
PR NewswireOncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities
PR NewswireOncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities

Oncolytics Biotech News

Oncolytics Biotech News: auf dieser Seite finden Sie alle Oncolytics Biotech News und Nachrichten zur Oncolytics Biotech Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Oncolytics Biotech News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Oncolytics Biotech News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.